
Opinion|Videos|December 8, 2023
EMERALD Subgroup Analysis in HER2-Low Metastatic Breast Cancer: Safety and Efficacy of Elacestrant
Author(s)Paolo Tarantino, MD
A comprehensive review of the safety and efficacy from a HER2-low subgroup analysis in the EMERALD Trial presented at SABCS 2023 and clinical implications in practice.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Illuminating the Sequence of Third-Line Therapies in Metastatic CRC
5











































